Neuroendocrine Differentiation and Response to PSMA-Targeted Radioligand Therapy in Advanced Metastatic Castration-Resistant Prostate Cancer: A Single-Center Retrospective Study
Thorsten Derlin, Rudolf A. Werner, Marcel Lafos, Christoph Henkenberens, Christoph A. J. von Klot, Jan M Sohns, Tobias L. Roß, Frank M. Bengel
Abstract
Neuroendocrine differentiation is associated with treatment failure and poor outcome in metastatic castration-resistant prostate cancer. We investigated the effect of circulating neuroendocrine biomarkers on the efficacy of prostate-specific membrane antigen (PSMA)–targeted radioligand therapy (RLT). <b>Methods:</b> Neuroendocrine biomarker profiles (progastrin-releasing peptide, neuron-specific enolase, and chromogranin-A) were analyzed in 50 patients commencing <sup>177</sup>Lu-PSMA-617 RLT. The primary endpoint was a prostate-specific antigen response in relation to baseline neuroendocrine marker profiles. An additional endpoint was progression-free survival. Tumor uptake on posttherapeutic scans, a known predictive marker for response, was used as a control variable. <b>Results:</b> Neuroendocrine biomarker profiles were abnormal in most patients. Neuroendocrine biomarker levels did not predict treatment failure or early progression (<i>P</i> ≥ 0.13). By contrast, intense PSMA-ligand uptake in metastases predicted both treatment response (<i>P</i> = 0.0030) and reduced risk of early progression (<i>P</i> = 0.0111). <b>Conclusion:</b> Neuroendocrine marker profiles do not predict an adverse outcome from RLT. By contrast, high ligand uptake was confirmed to be crucial for achieving a tumor response.